Logo image of MIRM

MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis

NASDAQ:MIRM - Nasdaq - US6047491013 - Common Stock - Currency: USD

43.42  -0.03 (-0.07%)

After market: 43 -0.42 (-0.97%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MIRM. MIRM was compared to 566 industry peers in the Biotechnology industry. MIRM may be in some trouble as it scores bad on both profitability and health. MIRM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MIRM had negative earnings in the past year.
MIRM had a positive operating cash flow in the past year.
In the past 5 years MIRM always reported negative net income.
MIRM had negative operating cash flow in 4 of the past 5 years.
MIRM Yearly Net Income VS EBIT VS OCF VS FCFMIRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

MIRM's Return On Assets of -13.11% is amongst the best of the industry. MIRM outperforms 84.45% of its industry peers.
MIRM has a Return On Equity of -38.97%. This is in the better half of the industry: MIRM outperforms 71.55% of its industry peers.
Industry RankSector Rank
ROA -13.11%
ROE -38.97%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
MIRM Yearly ROA, ROE, ROICMIRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

With an excellent Gross Margin value of 75.77%, MIRM belongs to the best of the industry, outperforming 83.04% of the companies in the same industry.
MIRM's Gross Margin has declined in the last couple of years.
MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
MIRM Yearly Profit, Operating, Gross MarginsMIRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MIRM has more shares outstanding
MIRM has more shares outstanding than it did 5 years ago.
MIRM has a better debt/assets ratio than last year.
MIRM Yearly Shares OutstandingMIRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MIRM Yearly Total Debt VS Total AssetsMIRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

MIRM has an Altman-Z score of 2.10. This is not the best score and indicates that MIRM is in the grey zone with still only limited risk for bankruptcy at the moment.
MIRM's Altman-Z score of 2.10 is fine compared to the rest of the industry. MIRM outperforms 72.97% of its industry peers.
A Debt/Equity ratio of 1.37 is on the high side and indicates that MIRM has dependencies on debt financing.
MIRM has a Debt to Equity ratio of 1.37. This is amonst the worse of the industry: MIRM underperforms 80.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Altman-Z 2.1
ROIC/WACCN/A
WACC9.65%
MIRM Yearly LT Debt VS Equity VS FCFMIRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.10 indicates that MIRM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.10, MIRM is doing worse than 63.60% of the companies in the same industry.
A Quick Ratio of 2.93 indicates that MIRM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.93, MIRM is not doing good in the industry: 63.78% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.1
Quick Ratio 2.93
MIRM Yearly Current Assets VS Current LiabilitesMIRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

MIRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.40%, which is quite impressive.
MIRM shows a strong growth in Revenue. In the last year, the Revenue has grown by 80.75%.
Measured over the past years, MIRM shows a very strong growth in Revenue. The Revenue has been growing by 160.12% on average per year.
EPS 1Y (TTM)53.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.76%
Revenue 1Y (TTM)80.75%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%42.93%

3.2 Future

Based on estimates for the next years, MIRM will show a very strong growth in Earnings Per Share. The EPS will grow by 35.10% on average per year.
MIRM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.41% yearly.
EPS Next Y47.84%
EPS Next 2Y34.79%
EPS Next 3Y34.25%
EPS Next 5Y35.1%
Revenue Next Year27.9%
Revenue Next 2Y24.03%
Revenue Next 3Y23.21%
Revenue Next 5Y26.41%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MIRM Yearly Revenue VS EstimatesMIRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
MIRM Yearly EPS VS EstimatesMIRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MIRM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRM Price Earnings VS Forward Price EarningsMIRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRM Per share dataMIRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

MIRM's earnings are expected to grow with 34.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.79%
EPS Next 3Y34.25%

More info and screens

0

5. Dividend

5.1 Amount

MIRM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (5/1/2025, 9:17:57 PM)

After market: 43 -0.42 (-0.97%)

43.42

-0.03 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners101.3%
Inst Owner Change0.06%
Ins Owners2.09%
Ins Owner Change0.12%
Market Cap2.15B
Analysts86.25
Price Target67.43 (55.3%)
Short Float %15.09%
Short Ratio12.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.44%
Min EPS beat(2)-99.42%
Max EPS beat(2)34.54%
EPS beat(4)1
Avg EPS beat(4)-20.84%
Min EPS beat(4)-99.42%
Max EPS beat(4)34.54%
EPS beat(8)3
Avg EPS beat(8)-45.16%
EPS beat(12)7
Avg EPS beat(12)-25.58%
EPS beat(16)8
Avg EPS beat(16)-70.27%
Revenue beat(2)2
Avg Revenue beat(2)4.46%
Min Revenue beat(2)0.89%
Max Revenue beat(2)8.03%
Revenue beat(4)3
Avg Revenue beat(4)1.78%
Min Revenue beat(4)-3.29%
Max Revenue beat(4)8.03%
Revenue beat(8)7
Avg Revenue beat(8)7.18%
Revenue beat(12)10
Avg Revenue beat(12)9.82%
Revenue beat(16)11
Avg Revenue beat(16)24.08%
PT rev (1m)2.66%
PT rev (3m)4.94%
EPS NQ rev (1m)-1.11%
EPS NQ rev (3m)-5.99%
EPS NY rev (1m)-2.33%
EPS NY rev (3m)-24.77%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)3.96%
Revenue NY rev (1m)1.78%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.37
P/FCF N/A
P/OCF 207.95
P/B 9.52
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)0.21
OCFY0.48%
SpS6.81
BVpS4.56
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.11%
ROE -38.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.77%
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.84%
Cap/Sales 6.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.1
Quick Ratio 2.93
Altman-Z 2.1
F-Score6
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.76%
EPS Next Y47.84%
EPS Next 2Y34.79%
EPS Next 3Y34.25%
EPS Next 5Y35.1%
Revenue 1Y (TTM)80.75%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%42.93%
Revenue Next Year27.9%
Revenue Next 2Y24.03%
Revenue Next 3Y23.21%
Revenue Next 5Y26.41%
EBIT growth 1Y19.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.63%
EBIT Next 3Y39.71%
EBIT Next 5YN/A
FCF growth 1Y88.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y114.55%
OCF growth 3YN/A
OCF growth 5YN/A